Larazotide
An oral peptide designed to tighten the gut lining in celiac disease. Its phase 3 trial was stopped in 2022 for lack of effect.
- Evidence
- Limited human research
- Half-life
- Not known
- Sources
- 2 cited
Is larazotide FDA-approved?
Investigational. Not FDA-approved.
Overview
Larazotide was built to stop gluten from loosening the gaps between gut cells. In a phase 2b trial, the lowest dose reduced celiac symptoms in people already on a gluten-free diet, while higher doses didn't beat placebo. The phase 3 trial was halted after an interim look.
How it works
It works in the gut to keep tight junctions, the seals between gut cells, from opening in response to gluten.
How long does larazotide stay in the body?
Acts locally in the gut; not absorbed much.
What it's studied for
- Celiac disease
- Gut barrier ("leaky gut")
Related: Thymalin, DSIP, VIP (Vasoactive Intestinal Peptide), Melanotan II.
Sources
The studies and prescribing labels this page is written from.
- Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet. Gastroenterology, 2015 PubMed
- Larazotide acetate for celiac disease: systematic review and meta-analysis. Clin Res Hepatol Gastroenterol, 2022 PubMed
